Current Clinical Trials.
- Splenic Hemangiosarcoma: Veterinary Cancer Group is actively enrolling dogs with splenic hemangiosarcoma into a partially-funded multi-institutional clinical trial. Qualified patients will have undergone a splenectomy, after which they will receive 5 doses of doxorubicin at 2-week intervals, followed by Palladia (toceranib) as an antiangiogenic therapy. The doxorubicin chemotherapy must be started within 21 days of surgery. Following completion of the 5 doxorubicin doses, the dogs will be restaged. Dogs that remain in clinical remission will begin prescribed Palladia as an antiangiogenic therapy.
- Nasal Tumors: We are currently conducting a clinical trial on the efficacy of palliative radiation for nasal tumors in canines. This is a non-funded prospective study. Palliative radiation therapy (five consecutive daily doses of radiation Monday through Friday) can reduce pain, inflammation, and epistaxis, and can lead to resolution of clinical signs with fewer side effects compared to surgery or definitive radiation.
- Appendicular Osteosarcoma: The study is designed to evaluate the efficacy of combining Carboplatin and Gemcitabine following amputation, as well as to evaluate the toxicity and treatment efficacy of this combination against various canine neoplasms.
- Transitional Cell Carcinoma: This partially funded study aims to determine whether different non-steroidal anti-inflammatory agents have the same efficacy against transitional cell carcinoma. Traditionally, piroxicam has been used; however, recent trials have shown other NSAIDs are also effective. The goals of this trial are to determine if piroxicam, a non-selective NSAID, and firocoxib, a highly selective NSAID, have equal efficacy in a controlled setting, and also to help establish the mechanisms through which NSAIDs work in cancer therapy. Both offices are recruiting dogs with bladder masses for this study. Dogs will receive piroxicam or firocoxib in combination with mitoxantrone chemotherapy, consistent with current standards of care.
- Obstructive Transitional Cell Carcinoma: This study is designed to alleviate urinary obstruction by utilizing palliative radiation therapy (five consecutive daily doses of radiation Monday through Friday), a urinary catheter, chemotherapy and piroxicam. Initial results have showed a 100 percent success rate at unblocking urinary obstruction in dogs with urinary transitional cell carcinoma.
- Feline Oral Squamous Cell Carcinoma: This study utilizes an accelerated definitive radiation protocol in conjunction with two doses of a radiosensitizer for feline oral squamous cell carcinoma. Accelerated radiation protocols are aimed at creating tumor cellular damage by overcoming the problem of tumor cellular repopulation, a characteristic that makes these tumors so aggressive. 14 doses of radiation are administered on a twice-daily protocol over the period of 7-10 days along with two doses of carboplatin. Initial results are promising and acute radiation side effects have been minimal.
- OSA in Greyhounds: The Veterinary Cancer Group is working together with the Greyhound Health and Wellness Program at The Ohio State University in order to determine if there is a genetic correlation among retired racing greyhounds that develop OSA. Five doses of chemotherapy agent will be provided free of charge to qualified greyhounds in exchange for a small blood sample.
For further information please contact any of our
veterinarians:
Mona Rosenberg, DVM, DACVIM (Oncology) •
Jarred Lyons, DVM, DACVR, (Radiation Oncology) •
Avenelle Turner, DVM, DACVIM (Oncology) • Mary
Davis, DVM, Practice Limited to Oncology • Sara
Fiocchi, DVM, Practice Limited to Oncology • Birgitte
Tan-Coleman, DVM, Practice Limited to Oncology • Jarrod
Vancil, DVM, Practice Limited to Oncology • Julie
Bulman-Fleming, DVM, Resident